The trial will assess a novel treatment combination in genetically defined high-risk myeloma patients.
The Multiple Myeloma Research Foundation launched the MMRF Answer Fund to engage researchers, clinicians, and patients in the search for better treatments.
The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
Researchers demonstrated the feasibility of finding multiple myeloma mutations with a new circulating tumor DNA sequencing method known as LB-Seq.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The company, which is collaborating with Myeloma Crowd, will use the newly-licensed minicircle DNA technology to develop therapies for multiple myeloma.
The partners aim to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve disease diagnosis, prognosis, and treatment.
The researchers' analysis of single circulating multiple myeloma tumor cells found that the results were similar to analysis of bone marrow biopsy samples.
The test is designed to replace gel electrophoresis assays currently used for measuring M-proteins, biomarkers for plasma cell diseases such as multiple myeloma.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.